Telix Pharmaceuticals TLX Insider Ownership

Updated Oct 5, 2026

Over the trailing 12 months, TLX insiders bought $1.02 million worth of shares (70.01K shares) in open-market trades, with no open-market sales.

• A count shows 2 insiders buying TLX stock on the open market over the past 12 months and none selling.
• Among Telix Pharmaceuticals' insiders, the largest open-market purchases in the past 12 months were by Christian Behrenbruch (MD & Group CEO), totaling $996,738 (67.94K shares), most recently on April 29, 2026.
• The newest open-market trade among Telix Pharmaceuticals insiders came on September 7, 2026, when Darren Charlton Smith (Group Chief Financial Officer) made a purchase of 2.07K shares for $19,998.
• Beyond open-market trades, insiders at Telix Pharmaceuticals acquired 1.11K shares through option exercises and conversions in the last 12 months.
• Business Quant data puts insider holdings in TLX at 20.76Mn shares across insiders' latest Form 4 filings, up 0.01% from 20.75Mn shares at the end of Q2 2026.
• Indirect holdings, through trusts, partnerships, family members and other entities, make up 99.93% (20.74Mn shares) of Telix Pharmaceuticals' insider total, with the other 0.07% (13.99K shares) held directly.
• Holdings in Telix Pharmaceuticals stock are reported by 2 insiders, the officers, directors and 10% owners who have filed a Form 4 in the past two years.
• Telix Pharmaceuticals' two biggest insider holders are Christian Behrenbruch (MD & Group CEO, 20.74Mn shares) and Darren Charlton Smith (Group Chief Financial Officer, 13.99K shares), based on their latest Form 4 filings.
• Christian Behrenbruch alone accounts for 99.93% of the shares held by Telix Pharmaceuticals insiders.
• Institutional holders reported 0.94% of Telix Pharmaceuticals' outstanding shares for Q2 2026.
• In the last 12 months, 3 Form 4 filings with transactions in TLX stock came from 2 insiders.
• The insider data for TLX reflects Form 4 filings through September 14, 2026.